ApogeeLogo.png
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
18 nov. 2024 07h30 HE | Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
ApogeeLogo.png
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
12 nov. 2024 07h00 HE | Apogee Therapeutics
Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support potential best-in-class profile On track to report Phase 2...
ApogeeLogo.png
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
04 nov. 2024 07h30 HE | Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
ApogeeLogo.png
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
24 oct. 2024 08h00 HE | Apogee Therapeutics
Pharmacokinetic data up to 9 months continue to support potential best-in-class profile, including a half-life of approximately 75 days, approximately three to five times that of currently approved...
ApogeeLogo.png
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
16 oct. 2024 07h00 HE | Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
ApogeeLogo.png
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
12 sept. 2024 07h00 HE | Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
ApogeeLogo.png
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
09 sept. 2024 07h00 HE | Apogee Therapeutics
SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for...
ApogeeLogo.png
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
19 août 2024 07h00 HE | Apogee Therapeutics, LLC
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in...
ApogeeLogo.png
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
12 août 2024 06h30 HE | Apogee Therapeutics, LLC
Continued advancement of pipeline and execution towards expected milestones, including APG777 16-week proof-of-concept data from the Phase 2 Part A trial in 2H 2025, APG808 interim Phase 1 data in 4Q...
ApogeeLogo.png
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
28 mai 2024 07h30 HE | Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...